Navigation Links
Menarini and Meyer United In The Search For Rare Cells

FLORENCE, Italy, Oct. 20, 2015 /PRNewswire/ -- Today marks the day on which the Menarini Pharma­ceutical Group donated an innovative research instrument to Florence's Meyer Children's Hospital. The DEPArray™ System will allow the hospital's pediatric oncology and neuro­science departments, headed by Claudio Favre and Renzo Guerrini, respectively, to conduct cutting-edge research. Each of their teams will be able to use the instrument to select and recover pure single cells, isolating them in several sample types such as blood, bone marrow, pleural fluid, and solid tissue biopsy.

The installation of the DEPArray system has opened up a new era in pediatric oncology and neurological research on epilepsy at Meyer. The instrument is unique and precise, and allows research teams to reveal even the most secret genetic mechanisms that lie within tumor cells, paving the way towards increasingly more personalized therapies that are by their very nature more effective.

The installation of the DEPArray system at the Meyer Children's Hospital will allow researchers to carry out in-depth studies on both circulating tumor cells and pediatric solid tumors for a greater knowledge of the genetics of cancer.

The DEPArray system is the only system capable of automatically isolating single, rare cells suspended in a number of different sample fluids. Circulating tumor cells, which can be found in blood samples, can be isolated and maintained intact, live and reproducible for genetic analysis. The system is extremely precise in selecting cells and is capable of selecting even single cells, allowing 100%  pure cell preparations.

"Thanks to the DEPArray system, we can isolate and select even very small quantities of pure circulating tumour cells," explained Favre. "These cells can provide us with important inform­ation as biomarkers for the evaluation of metastatic disease. In addition, we can also gain a better  understanding of the biological nature and the level of tumor aggressiveness, as well as being able to draw up a molecular profile for each individual patient so as to devise a personalized course of therapy better aimed at attacking the target cells."

Another field of research in which this system can be applied is the study of the role played by the immune system in the post-transplant stage through an analysis of biopsy tissues of the intestine. Favre added, "Our objective is to single out potential biological markers capable of foreseeing the onset of a dysregulation of the immune system or its degree of impairment so as to control the course of the disease."

In the Department of Neuroscience the DEPArray system will be used for epilepsy studies. "We shall be using this innovative system to extract DNA from cells that have been isolated within a number of different tissue samples, and particularly from brain cells taken from subjects who have undergone neurosurgery to treat their epilepsy," Guerrini explained. "We intend to study the genetic mutations responsible for the changes in the morphological and functional characteristics of the neurons that are the reasons behind epilepsy."

Research carried out different study groups around the world, including the team from Meyer, appears to corroborate the theory that epilepsy and a number of other brain malformations often originate from genetic alterations found in a limited number of brain cells. This phen­omenon, called "mosaicism," can only be investigated if one has direct access to brain cells to carry out high-resolution sequencing studies on the DNA found in these cells.

Alberto Zanobini, Director General of the Meyer Children's Hospital in Florence, said, "Thanks to the donation made by the Menarini Group, our hospital may now widen its horizons and open up new frontiers in the scientific research of the mechanisms behind epilepsy and the onset of tumors. Through this project we have forged a meaningful co-operation between an esteemed Italian company and our pediatric hospital, adopting world class technology of the highest level."

Lucia Aleotti, President of The Menarini Group, said, "We are here today to donate to the city's Meyer pediatric hospital, an exemplar of Italian excellence among children's hospitals, a system that is built upon a technology of great promise, born out of the research of two Italian engineers who united the potential of electronic engineering with biology to create a digital system for the management of human cells. The DEPArray system has been installed in top-level research centres in Europe, in the USA and Japan, and to be able to confer one of our systems into the expert hands of the researchers at Meyer is a source of great pride for us. This technology is capable of providing clear results in the genetic analyses of complex tumor tissue samples in young patients at Meyer. DEPArray allows researchers to get a better understanding of the genetics that lie behind tumour cells by providing them with results that are precise even in those cases where conventional methods fail, due to a poor cancer cell population in the blood sample, a sample which is too small to analyze, or the tumor cells in the biopsy tissue are simply not enough."


SOURCE The Menarini Group
Copyright©2015 PR Newswire.
All rights reserved

Related biology technology :

1. GenoSpace Expands Its Management Team by Appointing Daniel Meyer as Chief Financial Officer
2. United Therapeutics Announces Additional $500 Million Share Repurchase Program
3. United Therapeutics Announces Settlement of Patent Litigation with Sandoz Inc.
4. In'Tech Medical Announces Expansion of its Production-Equivalent Prototype Division, The Prototype Garage, in the United States
5. InSphero Granted Hanging Drop Patent in United States
6. BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health
7. P2i Settles United States Litigation
8. United Therapeutics Corporation To Present At The 2015 Wedbush PacGrow Healthcare Conference
9. United Therapeutics Corporation Reports Second Quarter 2015 Financial Results
10. United Therapeutics Corporation To Announce Second Quarter 2015 Financial Results Before Market Open On Tuesday, July 28, 2015
11. United States Genetic Diseases, Cancer, Forensic and Paternity Molecular Diagnostic Testing Markets Report 2014-2018
Post Your Comments:
(Date:11/13/2018)... ... November 13, 2018 , ... Aditya Humad, Managing Partner ... week that asserts it is still trending upward with growing valuations based on ... describes market consolidation, pricing pressure and increased competition as reasons often cited by ...
(Date:11/13/2018)... ... November 13, 2018 , ... Sharon ... Life Science® in Grants Pass, Oregon believes in the power of talk radio ... Water Life Science® sponsors the Power of Water® on talk radio every week ...
(Date:11/9/2018)... FRANCISCO (PRWEB) , ... November 08, 2018 , ... ... of Dr. Pablo Valenzuela, PhD, co-Founder, Chief Executive Officer and President of Andes ... doctors from around the world, Dr. Valenzuela brings to uBiome expertise on the ...
(Date:11/9/2018)... (PRWEB) , ... November 08, 2018 , ... ... integrator of custom industrial automation and IT solutions with 140 employees on both ... Automation Fair®, taking place at the Pennsylvania Convention Center on November 14 and ...
Breaking Biology Technology:
(Date:12/6/2018)... ... December 06, 2018 , ... Stewart has ... laboratory contract services, throughout his career. During his recent five-year tenure with InSphero ... and established the commercial laboratory operations in Brunswick, Maine. Through these experiences, Stewart ...
(Date:12/5/2018)... ... December 04, 2018 , ... Slone Partners, North America’s ... of Michael Mercer at Karius, Inc. as Chief Commercial Officer. Now responsible for ... at Karius' headquarters in Redwood City, California and report to CEO Mickey Kertesz ...
(Date:11/29/2018)... ... November 29, 2018 , ... ACEA Biosciences , now ... Engineering Research Center for Cell Manufacturing Technologies (CMaT). CMaT is a ... and technologies for the consistent, scalable and low-cost production of high-quality living therapeutic ...
Breaking Biology News(10 mins):